To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Prolonged-release famprid… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial

Journal article
Authors Raymond Hupperts
Jan Lycke
Christine Short
Claudio Gasperini
Manjit McNeill
Rossella Medori
Agata Tofil-Kaluza
Maria Hovenden
Lahar R. Mehta
Jacob Elkins
Published in Multiple Sclerosis
Volume 22
Pages 212-221
ISSN 1352-4585
Publication year 2016
Published at Institute of Neuroscience and Physiology
Pages 212-221
Language en
Keywords balance, Fampridine, multiple sclerosis, randomised clinical trial, walking
Subject categories Neurosciences


© SAGE Publications.Background: Mobility impairment is a common disability in MS and negatively impacts patients' lives. Objective: Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. Methods: MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Results: 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ≥7 (p = 0.0275), ≥8 (p = 0.0153) and ≥9 points (p = 0.0088) and TUG speed thresholds ≥10% (p = 0.0021) and ≥15% (p = 0.0262). PR-fampridine was well tolerated. Conclusions: PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?